Concepedia

S Aronoff

SA

9

Publications

1.3K

Citations

9

H-Index

1973

Active since

Affiliations

The University of Texas Southwestern Medical Center(Current)

Translational Research Institute for Metabolism and Diabetes

University of Utah

Research Institute of Dallas

University of Oxford

S Aronoff is an author at The University of Texas Southwestern Medical Center specializing in medicine, pharmacotherapy, and diabetes.

Top concepts

Publications per year

1973–2023

9

Publications

9

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

S Aronoff, Sidney Rosenblatt, Susan S. Braithwaite et al. · Diabetes Care · 2000 · 628 citations · Full text

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Ofri Mosenzon, Thalia Marie Blicher, Signe Rosenlund et al. · The Lancet Diabetes & Endocrinology · 2019 · 317 citations · Full text

, , +11

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Erin A. Bohula, Benjamin M. Scirica, Silvio E. Inzucchi et al. · The Lancet · 2018 · 94 citations · Full text

, , +9

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 88 citations · Full text

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 74 citations · Full text

Rows per page

1–5 of 9